OUR

CHALLENGE

A DEVASTATING DISEASE

​

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by abnormally high blood pressure in the blood vessels connected to and within the lungs.

 

In PAH, the muscles in the walls of the arteries in the lungs become thickened and the arteries become narrower, making it much harder for the heart to pump blood through the lungs.

​

PAH is a debilitating and life-threatening condition that shortens patient life expectancy because it often leads to severe breathing difficulties and heart failure.

 

Therapeutic options, although evolving, remain limited.

OUR

MISSION

NOVEL EFFECTIVE THERAPIES

​

ATXA Therapeutics Limited is focusing on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and for the PAH patient.

 

Headquartered in Dublin, Ireland, ATXA Therapeutics Limited is the culmination of over 20 years of extensive research and a proven track record in understanding of the biology and signaling of the human prostanoid receptors in the cardiovascular disease and oncology setting.

 

Our mission is to offer new hope to the PAH patient.